{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:17:52Z","timestamp":1789453072983,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.cgh.2019.09.041","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T11:19:16Z","timestamp":1570187956000},"page":"1291-1299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?"],"prefix":"10.1016","volume":"18","author":[{"given":"Severine","family":"Vermeire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5795","authenticated-orcid":false,"given":"Marla C.","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2019.09.041_bib1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","article-title":"Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Van Assche","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib2","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1111\/j.1572-0241.2005.41900.x","article-title":"A\u00a0cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine","volume":"100","author":"Dubinsky","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.041_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/ibd.21458","article-title":"Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease","volume":"17","author":"Haines","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-018-0282-x","article-title":"Golimumab Dried Blood Spot Analysis (GOUDA): a prospective trial showing excellent correlation with venepuncture samples and more detailed pharmacokinetic information","volume":"21","author":"Detrez","year":"2018","journal-title":"AAPS J"},{"key":"10.1016\/j.cgh.2019.09.041_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4155\/bio-2018-0010","article-title":"Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra\u00ae microsampler vs dried blood spot","volume":"10","author":"Bloem","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.cgh.2019.09.041_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bjd.18016","article-title":"Clinical response correlates with 4-week post injection ustekinumab concentrations in moderate-to-severe psoriasis patients","volume":"182","author":"Van den Berghe","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjz008","article-title":"Ustekinumab exposure-outcome analysis in Crohn\u2019s disease only in part explains limited endoscopic remission rates","volume":"13","author":"Verstockt","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib8","first-page":"101","article-title":"Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases","volume":"9","author":"Dreesen","year":"2017","journal-title":"Clin Pharmacol Adv Appl"},{"key":"10.1016\/j.cgh.2019.09.041_bib9","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/MIB.0000000000000709","article-title":"Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples","volume":"22","author":"Gils","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.09.041_bib12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/FTD.0000000000000074","article-title":"Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization","volume":"36","author":"Gils","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cgh.2019.09.041_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF\u03b1 antagonists","volume":"373","author":"Lallemand","year":"2011","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.cgh.2019.09.041_bib14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A\u00a0randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A\u00a0randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/FTD.0000000000000162","article-title":"Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays","volume":"37","author":"Van Stappen","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cgh.2019.09.041_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpba.2016.03.029","article-title":"Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays","volume":"125","author":"Bian","year":"2016","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.cgh.2019.09.041_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib19","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/MIB.0000000000000769","article-title":"Serum infliximab, antidrug antibodies, and tumor necrosis factor predict sustained response in pediatric Crohn's disease","volume":"22","author":"Stein","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MPG.0000000000002304","article-title":"Development of infliximab target concentrations during induction in pediatric Crohn disease patients","volume":"69","author":"Clarkston","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2019.09.041_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of anti-drug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jgh3.12000","article-title":"Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center","volume":"1","author":"Tighe","year":"2017","journal-title":"JGH Open"},{"key":"10.1016\/j.cgh.2019.09.041_bib23","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/MIB.0000000000001237","article-title":"Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort","volume":"23","author":"Gonczi","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/ecco-jcc\/jjw085","article-title":"Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis","volume":"10","author":"Farkas","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib25","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41395-018-0073-0","article-title":"Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the Poetic study","volume":"113","author":"Ungar","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.041_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/apt.14943","article-title":"Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing","volume":"48","author":"Verstockt","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/ecco-jcc\/jjz050","article-title":"Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn\u2019s disease: a prospective multicentre study","volume":"13","author":"Vande Casteele","year":"2019","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab induces endoscopic and histologic remission in patients with Crohn's disease","volume":"157","author":"L\u00f6wenberg","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study","volume":"47","author":"Yacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1016\/j.cgh.2019.02.042","article-title":"Concentrations of ustekinumab during induction therapy associate with remission in patients with Crohn's disease","volume":"17","author":"Soufflet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2019.05.029","article-title":"Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn's disease","volume":"18","author":"Dreesen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cgh.2014.09.031","article-title":"Factors associated with short- and long-term outcomes of therapy for Crohn's disease","volume":"13","author":"Reinisch","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.09.041_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","article-title":"First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis","volume":"51","author":"Kobayashi","year":"2016","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.041_bib35","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.cgh.2018.10.036","article-title":"Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis","volume":"17","author":"Vande Casteele","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib36","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.14318","article-title":"Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial","volume":"46","author":"Nakase","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cgh.2013.10.025","article-title":"Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/apt.14421","article-title":"Exposure\u2013response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn\u2019s disease","volume":"47","author":"Vande Casteele","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib42","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib43","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/apt.14410","article-title":"Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy","volume":"47","author":"Bar-Yoseph","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib44","first-page":"549","article-title":"Association of induction infliximab levels with clinical response in perianal Crohn's disease","volume":"11","author":"Davidov","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib45","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","article-title":"Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis","volume":"14","author":"Papamichael","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib47","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/ibd\/izy132","article-title":"Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn's disease","volume":"24","author":"Papamichael","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib48","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.09.041_bib49","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1097\/MIB.0b013e3182a77b41","article-title":"Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study","volume":"19","author":"Paul","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib50","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib51","article-title":"Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response","author":"Outtier","year":"2019","journal-title":"UEGW"},{"key":"10.1016\/j.cgh.2019.09.041_bib52","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1053\/j.gastro.2018.01.001","article-title":"Using proactive therapeutic drug monitoring of anti-tumor necrosis factor therapy in inflammatory bowel disease: from an old concept to a future standard of care?","volume":"154","author":"Papamichael","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib53","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib54","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib55","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib56","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib57","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's Disease","volume":"154","author":"D'Haens","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib58","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib59","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.041_bib60","article-title":"Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease","author":"Fernandes","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ecco-jcc\/jjy039","article-title":"Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease","volume":"12","author":"Papamichael","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/apt.15046","article-title":"Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring","volume":"49","author":"Lucidarme","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib63","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib64","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease","volume":"13","author":"Papamichael","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1208\/s12248-018-0257-y","article-title":"Individualized dosing of therapeutic monoclonal antibodies-a changing treatment paradigm?","volume":"20","author":"Strik","year":"2018","journal-title":"AAPS J"},{"key":"10.1016\/j.cgh.2019.09.041_bib66","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1007\/s00216-013-7154-0","article-title":"A\u00a0rapid assay for on-site monitoring of infliximab trough levels: a feasibility study","volume":"405","author":"Corstjens","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.cgh.2019.09.041_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2016.62","article-title":"Rapid test for infliximab drug concentration allows immediate dose adaptation","volume":"7","author":"Van Stappen","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.041_bib68","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1515\/cclm-2019-0202","article-title":"Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits","volume":"57","author":"Laserna-Mendieta","year":"2019","journal-title":"Clin Chem Lab Med May"},{"key":"10.1016\/j.cgh.2019.09.041_bib69","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/1756283X17722916","article-title":"Clinical performance of an infliximab rapid quantification assay","volume":"10","author":"Magro","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.041_bib70","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1007\/s10620-018-5144-y","article-title":"Comparison of point-of-care and classical immunoassays for the monitoring infliximab and antibodies against infliximab in IBD","volume":"63","author":"Nasser","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2019.09.041_bib71","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/apt.13757","article-title":"Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays","volume":"44","author":"Afonso","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.09.041_bib72","doi-asserted-by":"crossref","first-page":"S-1136","DOI":"10.1016\/S0016-5085(19)39804-X","article-title":"Tu1818 \u2013 ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment","volume":"156","author":"Bossuyt","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib73","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1097\/MIB.0000000000000434","article-title":"An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases","volume":"21","author":"Van Stappen","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.041_bib74","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of\u00a0inflammatory bowel diseases","volume":"153","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib75","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2014.12.010","article-title":"TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine","volume":"45","author":"Wicha","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cgh.2019.09.041_bib76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2019.09.041_bib77","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1208\/s12248-016-9994-y","article-title":"Pharmacokinetic dashboard-recommended dosing is different than standard of care dosing in infliximab-treated pediatric IBD patients","volume":"19","author":"Dubinsky","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.cgh.2019.09.041_bib78","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jcph.1069","article-title":"Prediction of individual serum infliximab concentrations in inflammatory bowel disease by a Bayesian dashboard system","volume":"58","author":"Eser","year":"2018","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2019.09.041_bib79","article-title":"DOP56 dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial","volume":"13","author":"Strik","year":"2019","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2019.09.041_bib80","doi-asserted-by":"crossref","first-page":"S-820","DOI":"10.1016\/S0016-5085(18)32802-6","article-title":"Pharmacokinetic dashboard-driven infliximab dosing in IBD: a prospective interventional study","volume":"154","author":"Dubinsky","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.09.041_bib81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/psp4.12049","article-title":"Good practices in model-informed drug discovery and development: practice, application, and documentation","volume":"5","author":"Marshall","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519310924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519310924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:32:01Z","timestamp":1761543121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356519310924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1542356519310924"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2019.09.041","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.09.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}